-
NORD - Pulmonary Arterial Hypertension
What is pulmonary arterial hypertension? Pulmonary arterial hypertension, or PAH, is a rare disorder characterized by high blood pressure in the blood vessels of the lungs, specifically the pulmonary arteries.
Find our full video library only on Osmosis: http://osms.it/more.
Join millions of current and future clinicians who learn by Osmosis, along with hundreds of universities around the world who partner with Osmosis from Elseiver to make medical and health education more engaging and efficient. We have unparalleled tools and materials to prepare you for success in school, on your board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. If you're interested in exploring an institutional partnership, visit osmosis.org/educators to request a personalized...
published: 06 Apr 2022
-
Hypertension | Clinical Medicine
Premium Member Resources: https://www.ninjanerd.org/lecture/hypertension
Ninja Nerds!
During the upcoming lecture, Professor Zach Murphy will delve into Hypertension (HTN), a medical condition classified as either Primary (Essential) or Secondary HTN. The lecture will extensively cover the various causes and pathophysiological mechanisms underlying HTN, as well as the potential complications that may arise. Additionally, the lecture will tackle the diagnostic process, highlighting critical physical examination findings that can aid in identifying HTN. Finally, the lecture will explore the various treatment options available for individuals with HTN.
Table of Contents:
0:00 Lab
0:07 Hypertension (HTN) Introduction
0:37 Pathophysiology | Primary (Essential) HTN
5:49 Pathophysiology | Secon...
published: 11 Mar 2024
-
What is Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension (PAH) is a specific type of pulmonary hypertension that is caused when the tiny arteries in your lung become thickened and narrowed. It is a rare, progressive lung disease, most common in women between the ages of 30-60 but can affect people of all ages. The American Lung Association is collaborating with Janssen to share new resources about PAH. Learn more at Lung.org/PAH.
published: 19 May 2023
-
Pulmonary Arterial Hypertension (PAH): Therapy Options Explained
Pulmonary arterial hypertension (PAH) is a progressive, irreversible disease that is frequently delayed in diagnosis and treatment. Watch to learn more about initiating combination therapy in patients with PAH.
More content about PAH is available for AMA PRA Category 1 Credit(s)™
Watch the Webinar ➤ https://www.pilotforpulmonary.org/9125-pah-video?utm_source=YouTube&utm_medium=Description&utm_campaign=+PAH_Animation&utm_id=9125
View the Activity ➤ https://www.pilotforpulmonary.org/component/virtuemart/disease-area/pulmonary-hypertension/improved-patient-outcomes-in-pah-detail
Pulmonary Arterial Hypertension Playlist ➤ https://www.youtube.com/playlist?list=PLYSugfOQLbfeqEM3JxH5k38qCAUn4O5V6
This video is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen...
published: 04 Jan 2022
-
Pulmonary Arterial Hypertension: Signs, symptoms and support
Dr Greg Kier provides a snapshot of Pulmonary Arterial Hypertension, what it is and highlights the symptoms, diagnosis and treatment.
published: 01 Nov 2017
-
Living with Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused when the tiny arteries in your lungs become thickened and narrowed. Hear Lindsay’s story about how she is successfully living her life with PAH. Support for this educational campaign is provided by Janssen. Learn more at Lung.org/PAH.
published: 31 May 2023
-
Treatment of Pulmonary Hypertension
This Harvard Medical School Continuing Education video examines these key questions: How does the World Health Organization (WHO) classify pulmonary hypertension risk categories? What is the role of vasoreactivity testing in determining treatment for pulmonary hypertension? What is the function of tertiary centers for evaluating pulmonary hypertension?
Dr. Jenna McNeill, MD, faculty at Massachusetts General Hospital, discusses how understanding pulmonary hypertension etiologies, as defined by the World Health Organization, aids in determining risk stratification and the role of vasoreactivity testing in recommending appropriate therapies. Approved medications for treating pulmonary arterial hypertension are reviewed as well as appropriate therapies for addressing pulmonary hypertension ca...
published: 01 Apr 2022
-
Pulmonary Arterial Hypertension (PAH) Pathophysiology: Treatment Pathways
In this program for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts the small pulmonary arteries, ultimately leading to reduced cardiac output and right heart failure. Medications are approved to treat 3 of the PAH pathways. Appropriate and timely use of a combination of PAH medications to improve risk status has been shown to extend patient’s 5-year survival.
This video uses medical animation to visually depict the impact of PAH on lung vessels and explains the mechanistic activity for each class of medication.
Content in the video includes:
• Pathophysiology of PAH
• Primary Disease Pathways
• Actions to Impact PAH Outcomes
published: 30 Nov 2023
-
Pulmonary Hypertension, Animation
(USMLE topics) Pulmonary arterial hypertension, PAH; Pulmonary hypertension caused by left-heart diseases; Pulmonary hypertension caused by lung disorders or hypoxemia; Pulmonary hypertension due to pulmonary artery obstruction. Classification, pathophysiology, symptoms, causes, mechanisms of pathogenesis, treatment.
Purchase a license to download a non-watermarked version of this video on AlilaMedicalMedia(dot)com
Check out our new Alila Academy - AlilaAcademy(dot)com - complete video courses with quizzes, PDFs, and downloadable images.
Voice by: Marty Henne
©Alila Medical Media. All rights reserved.
All images/videos by Alila Medical Media are for information purposes ONLY and are NOT intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of ...
published: 09 Nov 2020
-
Pathophysiology of Pulmonary Arterial Hypertension
In this video from the ATRIUM Cardiology Collaborative, Brent Reed provides an overview of the pathophysiology of pulmonary arterial hypertension.
published: 18 Feb 2016
6:15
NORD - Pulmonary Arterial Hypertension
What is pulmonary arterial hypertension? Pulmonary arterial hypertension, or PAH, is a rare disorder characterized by high blood pressure in the blood vessels o...
What is pulmonary arterial hypertension? Pulmonary arterial hypertension, or PAH, is a rare disorder characterized by high blood pressure in the blood vessels of the lungs, specifically the pulmonary arteries.
Find our full video library only on Osmosis: http://osms.it/more.
Join millions of current and future clinicians who learn by Osmosis, along with hundreds of universities around the world who partner with Osmosis from Elseiver to make medical and health education more engaging and efficient. We have unparalleled tools and materials to prepare you for success in school, on your board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. If you're interested in exploring an institutional partnership, visit osmosis.org/educators to request a personalized demo.
Follow us on social:
Facebook: http://osms.it/facebook
Twitter: http://osms.it/twitter
Instagram for med: http://osms.it/instagram
Instagram for nursing: https://osms.it/ignursing
TikTok: https://osms.it/tiktok
Linkedin: https://osms.it/linkedin
Our Vision: Everyone who cares for someone will learn by Osmosis.
Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission
Medical disclaimer: Osmosis from Elsevier does not provide medical advice. Osmosis from Elsevier and the content available on the Osmosis from Elsevier properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed healthcare provider. Always seek the advice of a physician or other qualified healthcare professional with any questions you have regarding a medical condition.
© 2024 Elsevier. All rights reserved.
https://wn.com/Nord_Pulmonary_Arterial_Hypertension
What is pulmonary arterial hypertension? Pulmonary arterial hypertension, or PAH, is a rare disorder characterized by high blood pressure in the blood vessels of the lungs, specifically the pulmonary arteries.
Find our full video library only on Osmosis: http://osms.it/more.
Join millions of current and future clinicians who learn by Osmosis, along with hundreds of universities around the world who partner with Osmosis from Elseiver to make medical and health education more engaging and efficient. We have unparalleled tools and materials to prepare you for success in school, on your board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. If you're interested in exploring an institutional partnership, visit osmosis.org/educators to request a personalized demo.
Follow us on social:
Facebook: http://osms.it/facebook
Twitter: http://osms.it/twitter
Instagram for med: http://osms.it/instagram
Instagram for nursing: https://osms.it/ignursing
TikTok: https://osms.it/tiktok
Linkedin: https://osms.it/linkedin
Our Vision: Everyone who cares for someone will learn by Osmosis.
Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission
Medical disclaimer: Osmosis from Elsevier does not provide medical advice. Osmosis from Elsevier and the content available on the Osmosis from Elsevier properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed healthcare provider. Always seek the advice of a physician or other qualified healthcare professional with any questions you have regarding a medical condition.
© 2024 Elsevier. All rights reserved.
- published: 06 Apr 2022
- views: 173347
41:56
Hypertension | Clinical Medicine
Premium Member Resources: https://www.ninjanerd.org/lecture/hypertension
Ninja Nerds!
During the upcoming lecture, Professor Zach Murphy will delve into Hypert...
Premium Member Resources: https://www.ninjanerd.org/lecture/hypertension
Ninja Nerds!
During the upcoming lecture, Professor Zach Murphy will delve into Hypertension (HTN), a medical condition classified as either Primary (Essential) or Secondary HTN. The lecture will extensively cover the various causes and pathophysiological mechanisms underlying HTN, as well as the potential complications that may arise. Additionally, the lecture will tackle the diagnostic process, highlighting critical physical examination findings that can aid in identifying HTN. Finally, the lecture will explore the various treatment options available for individuals with HTN.
Table of Contents:
0:00 Lab
0:07 Hypertension (HTN) Introduction
0:37 Pathophysiology | Primary (Essential) HTN
5:49 Pathophysiology | Secondary HTN
17:59 Stages of HTN (ACC/AHA Guidelines)
19:43 Complications | Cardiovascular Disease
25:36 Complications | Neurologic Disease
27:42 Complications | Renal Disease
30:01 Complications | Retinal Disease
31:54 Diagnostic Approach
33:48 Treatment Guideline of Chronic Hypertension
35:52 Antihypertensive based on Comorbidity
38:57 Treatment of Hypertensive Crisis
41:35 Comment, Like, SUBSCRIBE!
Retired Ninja Nerd Lectures:
https://youtu.be/pixsA_IgFgQ
https://youtu.be/cdxGgplZooM
https://youtu.be/HcbS7n1nkS8
Ninja Nerd Website | https://ninjanerd.org
Ninja Nerd Podcast | https://podcast.ninjanerd.org
Ninja Nerd Store | https://merch.ninjanerd.org
https://www.instagram.com/ninjanerdlectures/
https://www.tiktok.com/@ninjanerdlectures
https://www.facebook.com/NinjaNerdLectures/
https://twitter.com/@NinjaNerdSci
https://discord.gg/@TAsV8BGd
#ninjanerd #cardiovascular #hypertension
https://wn.com/Hypertension_|_Clinical_Medicine
Premium Member Resources: https://www.ninjanerd.org/lecture/hypertension
Ninja Nerds!
During the upcoming lecture, Professor Zach Murphy will delve into Hypertension (HTN), a medical condition classified as either Primary (Essential) or Secondary HTN. The lecture will extensively cover the various causes and pathophysiological mechanisms underlying HTN, as well as the potential complications that may arise. Additionally, the lecture will tackle the diagnostic process, highlighting critical physical examination findings that can aid in identifying HTN. Finally, the lecture will explore the various treatment options available for individuals with HTN.
Table of Contents:
0:00 Lab
0:07 Hypertension (HTN) Introduction
0:37 Pathophysiology | Primary (Essential) HTN
5:49 Pathophysiology | Secondary HTN
17:59 Stages of HTN (ACC/AHA Guidelines)
19:43 Complications | Cardiovascular Disease
25:36 Complications | Neurologic Disease
27:42 Complications | Renal Disease
30:01 Complications | Retinal Disease
31:54 Diagnostic Approach
33:48 Treatment Guideline of Chronic Hypertension
35:52 Antihypertensive based on Comorbidity
38:57 Treatment of Hypertensive Crisis
41:35 Comment, Like, SUBSCRIBE!
Retired Ninja Nerd Lectures:
https://youtu.be/pixsA_IgFgQ
https://youtu.be/cdxGgplZooM
https://youtu.be/HcbS7n1nkS8
Ninja Nerd Website | https://ninjanerd.org
Ninja Nerd Podcast | https://podcast.ninjanerd.org
Ninja Nerd Store | https://merch.ninjanerd.org
https://www.instagram.com/ninjanerdlectures/
https://www.tiktok.com/@ninjanerdlectures
https://www.facebook.com/NinjaNerdLectures/
https://twitter.com/@NinjaNerdSci
https://discord.gg/@TAsV8BGd
#ninjanerd #cardiovascular #hypertension
- published: 11 Mar 2024
- views: 294674
1:42
What is Pulmonary Arterial Hypertension?
Pulmonary Arterial Hypertension (PAH) is a specific type of pulmonary hypertension that is caused when the tiny arteries in your lung become thickened and narro...
Pulmonary Arterial Hypertension (PAH) is a specific type of pulmonary hypertension that is caused when the tiny arteries in your lung become thickened and narrowed. It is a rare, progressive lung disease, most common in women between the ages of 30-60 but can affect people of all ages. The American Lung Association is collaborating with Janssen to share new resources about PAH. Learn more at Lung.org/PAH.
https://wn.com/What_Is_Pulmonary_Arterial_Hypertension
Pulmonary Arterial Hypertension (PAH) is a specific type of pulmonary hypertension that is caused when the tiny arteries in your lung become thickened and narrowed. It is a rare, progressive lung disease, most common in women between the ages of 30-60 but can affect people of all ages. The American Lung Association is collaborating with Janssen to share new resources about PAH. Learn more at Lung.org/PAH.
- published: 19 May 2023
- views: 14271
4:06
Pulmonary Arterial Hypertension (PAH): Therapy Options Explained
Pulmonary arterial hypertension (PAH) is a progressive, irreversible disease that is frequently delayed in diagnosis and treatment. Watch to learn more about in...
Pulmonary arterial hypertension (PAH) is a progressive, irreversible disease that is frequently delayed in diagnosis and treatment. Watch to learn more about initiating combination therapy in patients with PAH.
More content about PAH is available for AMA PRA Category 1 Credit(s)™
Watch the Webinar ➤ https://www.pilotforpulmonary.org/9125-pah-video?utm_source=YouTube&utm_medium=Description&utm_campaign=+PAH_Animation&utm_id=9125
View the Activity ➤ https://www.pilotforpulmonary.org/component/virtuemart/disease-area/pulmonary-hypertension/improved-patient-outcomes-in-pah-detail
Pulmonary Arterial Hypertension Playlist ➤ https://www.youtube.com/playlist?list=PLYSugfOQLbfeqEM3JxH5k38qCAUn4O5V6
This video is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Developed for physicians and advance practice providers.
https://wn.com/Pulmonary_Arterial_Hypertension_(Pah)_Therapy_Options_Explained
Pulmonary arterial hypertension (PAH) is a progressive, irreversible disease that is frequently delayed in diagnosis and treatment. Watch to learn more about initiating combination therapy in patients with PAH.
More content about PAH is available for AMA PRA Category 1 Credit(s)™
Watch the Webinar ➤ https://www.pilotforpulmonary.org/9125-pah-video?utm_source=YouTube&utm_medium=Description&utm_campaign=+PAH_Animation&utm_id=9125
View the Activity ➤ https://www.pilotforpulmonary.org/component/virtuemart/disease-area/pulmonary-hypertension/improved-patient-outcomes-in-pah-detail
Pulmonary Arterial Hypertension Playlist ➤ https://www.youtube.com/playlist?list=PLYSugfOQLbfeqEM3JxH5k38qCAUn4O5V6
This video is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Developed for physicians and advance practice providers.
- published: 04 Jan 2022
- views: 5509
1:52
Pulmonary Arterial Hypertension: Signs, symptoms and support
Dr Greg Kier provides a snapshot of Pulmonary Arterial Hypertension, what it is and highlights the symptoms, diagnosis and treatment.
Dr Greg Kier provides a snapshot of Pulmonary Arterial Hypertension, what it is and highlights the symptoms, diagnosis and treatment.
https://wn.com/Pulmonary_Arterial_Hypertension_Signs,_Symptoms_And_Support
Dr Greg Kier provides a snapshot of Pulmonary Arterial Hypertension, what it is and highlights the symptoms, diagnosis and treatment.
- published: 01 Nov 2017
- views: 8962
2:39
Living with Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused when the tiny arteries in your lungs become thickened and narrowed. Hear Lindsay’s ...
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused when the tiny arteries in your lungs become thickened and narrowed. Hear Lindsay’s story about how she is successfully living her life with PAH. Support for this educational campaign is provided by Janssen. Learn more at Lung.org/PAH.
https://wn.com/Living_With_Pulmonary_Arterial_Hypertension_(Pah)
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused when the tiny arteries in your lungs become thickened and narrowed. Hear Lindsay’s story about how she is successfully living her life with PAH. Support for this educational campaign is provided by Janssen. Learn more at Lung.org/PAH.
- published: 31 May 2023
- views: 21105
8:42
Treatment of Pulmonary Hypertension
This Harvard Medical School Continuing Education video examines these key questions: How does the World Health Organization (WHO) classify pulmonary hypertensio...
This Harvard Medical School Continuing Education video examines these key questions: How does the World Health Organization (WHO) classify pulmonary hypertension risk categories? What is the role of vasoreactivity testing in determining treatment for pulmonary hypertension? What is the function of tertiary centers for evaluating pulmonary hypertension?
Dr. Jenna McNeill, MD, faculty at Massachusetts General Hospital, discusses how understanding pulmonary hypertension etiologies, as defined by the World Health Organization, aids in determining risk stratification and the role of vasoreactivity testing in recommending appropriate therapies. Approved medications for treating pulmonary arterial hypertension are reviewed as well as appropriate therapies for addressing pulmonary hypertension caused by left heart disease, lung disease, or chronic thromboembolic disease.
00:00 | Introduction
00:26 | World Health Organization functional classifications
00:37 | Recommendations for Group 1
05:06 | Recommendations for Group 2
06:00 | Recommendations for Group 3
07:03 | Recommendations for Group 4
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.
References:
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016 69(2):177.
McLaughlin VV, Archer SL, Badesch DB, et al. American College of Cardiology Foundation Task Force on Expert Consensus, A. American Heart, P. American College of Chest, I. American Thoracic Society and A. Pulmonary Hypertension. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17): 1573-1619.
Thomas CA, Anderson RJ, Condon DF, de Jesus Perez VA. Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. Pulm Ther. 2020;6(1):9-22.
Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-844.
Nathan, S. D., A. Waxman and V. Tapson. Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply. N Engl J Med. 2021;384(19): 1871-1872.
Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-329.
Notice: At this time, the content in this video is not accredited.
https://wn.com/Treatment_Of_Pulmonary_Hypertension
This Harvard Medical School Continuing Education video examines these key questions: How does the World Health Organization (WHO) classify pulmonary hypertension risk categories? What is the role of vasoreactivity testing in determining treatment for pulmonary hypertension? What is the function of tertiary centers for evaluating pulmonary hypertension?
Dr. Jenna McNeill, MD, faculty at Massachusetts General Hospital, discusses how understanding pulmonary hypertension etiologies, as defined by the World Health Organization, aids in determining risk stratification and the role of vasoreactivity testing in recommending appropriate therapies. Approved medications for treating pulmonary arterial hypertension are reviewed as well as appropriate therapies for addressing pulmonary hypertension caused by left heart disease, lung disease, or chronic thromboembolic disease.
00:00 | Introduction
00:26 | World Health Organization functional classifications
00:37 | Recommendations for Group 1
05:06 | Recommendations for Group 2
06:00 | Recommendations for Group 3
07:03 | Recommendations for Group 4
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.
References:
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016 69(2):177.
McLaughlin VV, Archer SL, Badesch DB, et al. American College of Cardiology Foundation Task Force on Expert Consensus, A. American Heart, P. American College of Chest, I. American Thoracic Society and A. Pulmonary Hypertension. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17): 1573-1619.
Thomas CA, Anderson RJ, Condon DF, de Jesus Perez VA. Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. Pulm Ther. 2020;6(1):9-22.
Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-844.
Nathan, S. D., A. Waxman and V. Tapson. Inhaled Treprostinil in Group 3 Pulmonary Hypertension. Reply. N Engl J Med. 2021;384(19): 1871-1872.
Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-329.
Notice: At this time, the content in this video is not accredited.
- published: 01 Apr 2022
- views: 15394
7:13
Pulmonary Arterial Hypertension (PAH) Pathophysiology: Treatment Pathways
In this program for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts...
In this program for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts the small pulmonary arteries, ultimately leading to reduced cardiac output and right heart failure. Medications are approved to treat 3 of the PAH pathways. Appropriate and timely use of a combination of PAH medications to improve risk status has been shown to extend patient’s 5-year survival.
This video uses medical animation to visually depict the impact of PAH on lung vessels and explains the mechanistic activity for each class of medication.
Content in the video includes:
• Pathophysiology of PAH
• Primary Disease Pathways
• Actions to Impact PAH Outcomes
https://wn.com/Pulmonary_Arterial_Hypertension_(Pah)_Pathophysiology_Treatment_Pathways
In this program for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts the small pulmonary arteries, ultimately leading to reduced cardiac output and right heart failure. Medications are approved to treat 3 of the PAH pathways. Appropriate and timely use of a combination of PAH medications to improve risk status has been shown to extend patient’s 5-year survival.
This video uses medical animation to visually depict the impact of PAH on lung vessels and explains the mechanistic activity for each class of medication.
Content in the video includes:
• Pathophysiology of PAH
• Primary Disease Pathways
• Actions to Impact PAH Outcomes
- published: 30 Nov 2023
- views: 6532
4:28
Pulmonary Hypertension, Animation
(USMLE topics) Pulmonary arterial hypertension, PAH; Pulmonary hypertension caused by left-heart diseases; Pulmonary hypertension caused by lung disorders or hy...
(USMLE topics) Pulmonary arterial hypertension, PAH; Pulmonary hypertension caused by left-heart diseases; Pulmonary hypertension caused by lung disorders or hypoxemia; Pulmonary hypertension due to pulmonary artery obstruction. Classification, pathophysiology, symptoms, causes, mechanisms of pathogenesis, treatment.
Purchase a license to download a non-watermarked version of this video on AlilaMedicalMedia(dot)com
Check out our new Alila Academy - AlilaAcademy(dot)com - complete video courses with quizzes, PDFs, and downloadable images.
Voice by: Marty Henne
©Alila Medical Media. All rights reserved.
All images/videos by Alila Medical Media are for information purposes ONLY and are NOT intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.
Pulmonary hypertension refers to high blood pressure in the blood vessels of the lungs.
The lungs receive oxygen-poor blood from the right side of the heart. After being reoxygenated, oxygen-rich blood returns to the left side of the heart to be pumped out to the body.
Normally, the right ventricle pumps against a low-resistance pulmonary circuit. Increased blood pressure in the lungs results in a greater resistance. The right heart must work harder to push blood through pulmonary arteries. This causes the right ventricle to thicken, enlarge and eventually fail, a condition known as right-sided heart failure.
The most common symptom of pulmonary hypertension is shortness of breath during exertion. Other signs may include dizziness, fainting, and chest pressure or pain. Swelling of legs may occur when right-sided heart failure has developed.
Pulmonary hypertension is classified into 5 groups, based on the cause and mechanism of the disease.
Group 1: Pulmonary arterial hypertension, PAH. PAH affects mostly the arterioles, the smaller arteries of the lungs. PAH can be caused by a number of factors, including genetics, certain drugs, and other health conditions. For many cases, the cause is unknown. Regardless of the underlying cause, however, the group shares similar pathological changes. These include: increased activities of vasoconstrictors, decreased activities of vasodilators, and vascular wall remodeling as a result of endothelial and smooth muscle proliferation and chronic inflammation. In addition, the increased vascular pressure injures the endothelium, activating coagulation, producing blood clots that further obstruct blood flow.
Group 2: Pulmonary hypertension caused by left-heart diseases. A number of conditions can lead to dysfunction of the left side of the heart, affecting its ability to pump effectively or to fill properly. When left-heart function is compromised, blood backs up in the lungs, where it came from, causing congestion and increased pulmonary pressure. As this happens, fluid leaks from blood vessels to lung tissue, resulting in pulmonary edema. Accumulation of fluid in the alveoli impedes the gas exchange process, causing respiratory symptoms.
Group 3: Pulmonary hypertension caused by lung disorders or low blood oxygen. When oxygen level is low, pulmonary vessels constrict in an attempt to shunt blood to better-ventilated regions of the lung. Conditions or circumstances that result in low blood oxygen are risk factors for developing pulmonary hypertension. Lung disorders, such as chronic obstructive pulmonary disease, also cause lung tissue damage, inflammation and loss of capillaries, which further contribute to disease development.
Group 4: Pulmonary hypertension due to pulmonary artery obstruction. Certain chronic disorders can repeatedly produce blood clots, typically in deep leg veins. The clots may travel to the lungs, blocking pulmonary arteries. If these clots do not resolve completely, pulmonary vessels can become narrower and stiffer. Pulmonary arteries may also be obstructed by tumors, parasites, or foreign particles.
Group 5 includes pulmonary hypertension by all other mechanisms.
Treatment should be aimed at the underlying cause whenever possible. Anticoagulants may be given to reduce the risk of blood clots. Vasodilators and supplemental oxygen can help relieve symptoms. However, vasodilators are only effective for certain types of pulmonary hypertension and should be tested for effectiveness before they can be prescribed.
https://wn.com/Pulmonary_Hypertension,_Animation
(USMLE topics) Pulmonary arterial hypertension, PAH; Pulmonary hypertension caused by left-heart diseases; Pulmonary hypertension caused by lung disorders or hypoxemia; Pulmonary hypertension due to pulmonary artery obstruction. Classification, pathophysiology, symptoms, causes, mechanisms of pathogenesis, treatment.
Purchase a license to download a non-watermarked version of this video on AlilaMedicalMedia(dot)com
Check out our new Alila Academy - AlilaAcademy(dot)com - complete video courses with quizzes, PDFs, and downloadable images.
Voice by: Marty Henne
©Alila Medical Media. All rights reserved.
All images/videos by Alila Medical Media are for information purposes ONLY and are NOT intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.
Pulmonary hypertension refers to high blood pressure in the blood vessels of the lungs.
The lungs receive oxygen-poor blood from the right side of the heart. After being reoxygenated, oxygen-rich blood returns to the left side of the heart to be pumped out to the body.
Normally, the right ventricle pumps against a low-resistance pulmonary circuit. Increased blood pressure in the lungs results in a greater resistance. The right heart must work harder to push blood through pulmonary arteries. This causes the right ventricle to thicken, enlarge and eventually fail, a condition known as right-sided heart failure.
The most common symptom of pulmonary hypertension is shortness of breath during exertion. Other signs may include dizziness, fainting, and chest pressure or pain. Swelling of legs may occur when right-sided heart failure has developed.
Pulmonary hypertension is classified into 5 groups, based on the cause and mechanism of the disease.
Group 1: Pulmonary arterial hypertension, PAH. PAH affects mostly the arterioles, the smaller arteries of the lungs. PAH can be caused by a number of factors, including genetics, certain drugs, and other health conditions. For many cases, the cause is unknown. Regardless of the underlying cause, however, the group shares similar pathological changes. These include: increased activities of vasoconstrictors, decreased activities of vasodilators, and vascular wall remodeling as a result of endothelial and smooth muscle proliferation and chronic inflammation. In addition, the increased vascular pressure injures the endothelium, activating coagulation, producing blood clots that further obstruct blood flow.
Group 2: Pulmonary hypertension caused by left-heart diseases. A number of conditions can lead to dysfunction of the left side of the heart, affecting its ability to pump effectively or to fill properly. When left-heart function is compromised, blood backs up in the lungs, where it came from, causing congestion and increased pulmonary pressure. As this happens, fluid leaks from blood vessels to lung tissue, resulting in pulmonary edema. Accumulation of fluid in the alveoli impedes the gas exchange process, causing respiratory symptoms.
Group 3: Pulmonary hypertension caused by lung disorders or low blood oxygen. When oxygen level is low, pulmonary vessels constrict in an attempt to shunt blood to better-ventilated regions of the lung. Conditions or circumstances that result in low blood oxygen are risk factors for developing pulmonary hypertension. Lung disorders, such as chronic obstructive pulmonary disease, also cause lung tissue damage, inflammation and loss of capillaries, which further contribute to disease development.
Group 4: Pulmonary hypertension due to pulmonary artery obstruction. Certain chronic disorders can repeatedly produce blood clots, typically in deep leg veins. The clots may travel to the lungs, blocking pulmonary arteries. If these clots do not resolve completely, pulmonary vessels can become narrower and stiffer. Pulmonary arteries may also be obstructed by tumors, parasites, or foreign particles.
Group 5 includes pulmonary hypertension by all other mechanisms.
Treatment should be aimed at the underlying cause whenever possible. Anticoagulants may be given to reduce the risk of blood clots. Vasodilators and supplemental oxygen can help relieve symptoms. However, vasodilators are only effective for certain types of pulmonary hypertension and should be tested for effectiveness before they can be prescribed.
- published: 09 Nov 2020
- views: 285385
4:14
Pathophysiology of Pulmonary Arterial Hypertension
In this video from the ATRIUM Cardiology Collaborative, Brent Reed provides an overview of the pathophysiology of pulmonary arterial hypertension.
In this video from the ATRIUM Cardiology Collaborative, Brent Reed provides an overview of the pathophysiology of pulmonary arterial hypertension.
https://wn.com/Pathophysiology_Of_Pulmonary_Arterial_Hypertension
In this video from the ATRIUM Cardiology Collaborative, Brent Reed provides an overview of the pathophysiology of pulmonary arterial hypertension.
- published: 18 Feb 2016
- views: 43720